HilleVax, Inc. (HLVX) announced on Monday that the Phase 2b NEST-IN1 study of HIL-214, the company's vaccine candidate aimed at preventing acute gastroenteritis caused by norovirus infection in infants, failed to meet its primary objective. In response to this news, the stock plummeted over 86% in pre-market trading, falling to $1.94.
The company has decided to halt further development of HIL-214 for use in infants.
The study's primary endpoint—efficacy against moderate or severe acute gastroenteritis events attributed to GI.1 or GII.4 norovirus genotypes—was not met.
However, HilleVax is evaluating the potential for continued development of HIL-214 and exploring HIL-216, the company's Phase 1-ready vaccine candidate for adults.
HilleVax shares closed at $14.06 on Friday, having declined by 0.28%. Over the past year, the stock has fluctuated between $9.94 and $20.22.
